10 December 2021 | In this 1-hour webinar, featured speakers will demonstrate end-to-end how to develop a quantitative assay in HALO and transition it into clinical trials using HALO AP.
Bench-to-Bedside Transition of Novel HALO® Assays into Clinical Trials with HALO AP® Read More »
Albuquerque, NM, USA and Nottingham, UK, 1 July, 2021 – Following a formal tender process, Nottingham University Hospitals (NUH) NHS Trust today announced the selection of Indica Labs to aid in full digitisation of the pathology workflow. Indica Labs will deliver its leading digital pathology software, HALO AP®, fully integrated with existing hospital systems, alongside multiple Hamamatsu Nanozoomer scanners.
ALBUQUERQUE, NM and TEL AVIV, Israel – May 20, 2021 – Indica Labs, an industry leader in quantitative digital pathology & image management solutions, and Ibex Medical Analytics, a pioneer in artificial intelligence (AI) based cancer diagnostics, announced an agreement to integrate the Galen™ AI-based cancer diagnostics platform into the HALO AP® digital pathology workflow platform.
1 April 2021 | The Indica Labs software products have a number of additional tools to extend the utility of our products beyond the HALO user interface most users are familiar with. These tools allow users to query the underlying database for metadata imported to HALO Link, integrate with LIMS, plugin convolutional neural networks not available in HALO, write analysis modules from scratch, and more.
HALO Image Analysis Masterclass Series: Indica Labs Tech Toolbox Webinar Read More »
November 24, 2020
12:20 CET
ESDIP presents their first-ever workshop – Going into digital pathology in pandemic times: all you need to know for implementation. This online, one- track event primarily serves to help those who wish to start a digital workflow in their pathology laboratories of pathology, with the presentation of models of successful implementation. Don’t miss Ms. McKinley’s presentation on HALO AP and our integrated workflow.
19 November 2020 8:00 PST | 11:00 EST | 16:00 GMT | As interest in digital pathology continues to grow within the research community we seek to centralize resources in the cloud to offer a collaborative platform with enhanced functionality.
16 June 2020 | In this webinar, Indica Labs’ HALO AP Product Manager, Eric Runde, will discuss these capabilities and the nationwide deployment of HALO AP for quantitative IHC testing for breast cancer and colorectal cancer panels at NeoGenomics. Dr. Sally Agersborg, Medical Director at NeoGenomics, will discuss considerations when selecting an image analysis platform and approaches to validation of image analysis for a multi-site laboratory.
8-11 June 2020 | In lieu of our scheduled onsite user group meetings, Indica Labs is pleased to announce our 2020 US Virtual HALO User Group Meeting. To make participation easier for our US audience, we will break down the user groups into four one-hour webinars over three days starting at 9 AM PDT/12 PM EDT.
19-21 May 2020 | In lieu of our scheduled onsite user group meetings, Indica Labs is pleased to announce our 2020 European Virtual HALO User Group Meeting. To make participation more convenient for our European audience, we are breaking the user group into three one-hour webinars over three days, 19-21st May, starting at 11 AM GMT each day.
Virtual European User Group Meeting Read More »
Albuquerque, NM (April 3, 2020) – Indica Labs, the leading provider of computational pathology software, is pleased to announce the formal release of its HALO AP™ Anatomic Pathology platform at NeoGenomics Laboratories, Inc.
HALO AP™ was developed by Indica Labs to address the needs of Anatomic Pathology labs. Offering a full range of tissue-based assays and workflows, the platform can be fully integrated within existing LIS solutions or can operate as a standalone case management system. HALO AP adds support for clinical trials, tumor boards, secondary consults, AI-assisted workflows, and quantitative analysis of custom laboratory developed tests (LDTs), from basic immunohistochemistry (IHC) through to novel, multiplexed immune-oncology assays.
